In contrast to Mcl-1 upregulation upon treatment with VU661013, we did not see upregulation of Bcl-2 or Bcl-xL in ER+ breast cancer cells treated with the Mcl-1 inhibitor. This evidence concerns the gene BCL2L1 and breast carcinoma.